Rare variants and HLA haplotypes associated in patients with neuromyelitis optica spectrum disorders

Neuromyelitis optica spectrum disorders (NMOSD) are rare, debilitating autoimmune diseases of the central nervous system. Many NMOSD patients have antibodies to Aquaporin-4 (AQP4). Prior studies show associations of NMOSD with individual Human Leukocyte Antigen (HLA) alleles and with mutations in the complement pathway and potassium channels. HLA allele associations with NMOSD are inconsistent between populations, suggesting complex relationships between the identified alleles and risk of disease. We used a retrospective case-control approach to identify contributing genetic variants in patients who met the diagnostic criteria for NMOSD and their unaffected family members. Potentially deleterious variants identified in NMOSD patients were compared to members of their families who do not have the disease and to existing databases of human genetic variation. HLA sequences from patients from Belgrade, Serbia, were compared to the frequency of HLA haplotypes in the general population in Belgrade. We analyzed exome sequencing on 40 NMOSD patients and identified rare inherited variants in the complement pathway and potassium channel genes. Haplotype analysis further detected two haplotypes, HLA-A*01, B*08, DRB1*03 and HLA-A*01, B*08, C*07, DRB1*03, DQB1*02, which were more prevalent in NMOSD patients than in unaffected individuals. In silico modeling indicates that HLA molecules within these haplotypes are predicted to bind AQP4 at several sites, potentially contributing to the development of autoimmunity. Our results point to possible autoimmune and neurodegenerative mechanisms that cause NMOSD, and can be used to investigate potential NMOSD drug targets.

[1]  B. Feng,et al.  Multi-Level Analyses of Genome-Wide Association Study to Reveal Significant Risk Genes and Pathways in Neuromyelitis Optica Spectrum Disorder , 2021, Frontiers in Genetics.

[2]  J. Shendure,et al.  CADD-Splice—improving genome-wide variant effect prediction using deep learning-derived splice scores , 2021, Genome Medicine.

[3]  C. Vasconcelos,et al.  Neuromyelitis optica is an HLA associated disease different from Multiple Sclerosis: a systematic review with meta-analysis , 2021, Scientific reports.

[4]  J. Kira,et al.  Genetic factors for susceptibility to and manifestations of neuromyelitis optica , 2020, Annals of clinical and translational neurology.

[5]  E. Meinl,et al.  Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases. , 2020, Current opinion in neurology.

[6]  M. Daly,et al.  Exome sequencing in schizophrenia-affected parent-offspring trios reveals risk conferred by protein-coding de novo mutations , 2019, Nature Neuroscience.

[7]  Thawfeek M. Varusai,et al.  The reactome pathway knowledgebase , 2019, Nucleic Acids Res..

[8]  K. Fujihara,et al.  Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat , 2018, Acta Neuropathologica.

[9]  M. Reindl,et al.  Myelin oligodendrocyte glycoprotein antibodies in neurological disease , 2018, Nature Reviews Neurology.

[10]  R. Hampson,et al.  Fibronectin Produced by Cerebral Endothelial and Vascular Smooth Muscle Cells Contributes to Perivascular Extracellular Matrix in Late-Delayed Radiation-Induced Brain Injury , 2018, Radiation Research.

[11]  J. Greenbaum,et al.  Improved methods for predicting peptide binding affinity to MHC class II molecules , 2018, Immunology.

[12]  Robert E Handsaker,et al.  A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica , 2018, Nature Communications.

[13]  Jinyu Wu,et al.  Identification of de novo germline mutations and causal genes for sporadic diseases using trio‐based whole‐exome/genome sequencing , 2018, Biological reviews of the Cambridge Philosophical Society.

[14]  H. Lassmann,et al.  Mechanisms for lesion localization in neuromyelitis optica spectrum disorders , 2018, Current opinion in neurology.

[15]  J. Granados,et al.  Neuromyelitis Optica (NMO IgG+) and Genetic Susceptibility, Potential Ethnic Influences. , 2018, Central nervous system agents in medicinal chemistry.

[16]  V. Sutton,et al.  Mutations in Fibronectin Cause a Subtype of Spondylometaphyseal Dysplasia with "Corner Fractures". , 2017, American journal of human genetics.

[17]  Hoang T. Nguyen,et al.  Integrated Bayesian analysis of rare exonic variants to identify risk genes for schizophrenia and neurodevelopmental disorders , 2017, bioRxiv.

[18]  B. Weinshenker,et al.  Neuromyelitis Spectrum Disorders , 2017, Mayo Clinic proceedings.

[19]  B. Weinshenker,et al.  Neuromyelitis optica spectrum disorder diagnostic criteria: Sensitivity and specificity are both important , 2017, Multiple sclerosis.

[20]  F. Paul,et al.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin , 2016, Journal of Neuroinflammation.

[21]  Trevor Hastie,et al.  REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. , 2016, American journal of human genetics.

[22]  D. Conrad,et al.  Genomewide significance testing of variation from single case exomes , 2016, Nature Genetics.

[23]  K. Fujihara,et al.  Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD , 2016, Acta neuropathologica communications.

[24]  V. Majithia,et al.  Neuromyelitis Optica (Devic’s Syndrome): an Appraisal , 2016, Current Rheumatology Reports.

[25]  T. Ben-Hur,et al.  Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel , 2016, Journal of Neuroimmunology.

[26]  Morten Nielsen,et al.  Gapped sequence alignment using artificial neural networks: application to the MHC class I system , 2016, Bioinform..

[27]  James Y. Zou Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[28]  K. Fujihara,et al.  Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS , 2015, Acta Neuropathologica.

[29]  J. Tolmie,et al.  Haploinsufficiency of the NOTCH1 Receptor as a Cause of Adams–Oliver Syndrome With Variable Cardiac Anomalies , 2015, Circulation. Cardiovascular genetics.

[30]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[31]  L. Kappos,et al.  Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype , 2015, Journal of Neuroinflammation.

[32]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[33]  John T. Chang,et al.  A gp130–Src–YAP module links inflammation to epithelial regeneration , 2015, Nature.

[34]  Andrew R. Jones,et al.  Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations , 2014, Nucleic Acids Res..

[35]  K. Matsushima,et al.  CCR4 and its ligands: from bench to bedside. , 2015, International immunology.

[36]  M. Papadopoulos,et al.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies , 2014, Nature Reviews Neurology.

[37]  D. Popadic,et al.  HLA-A, -B, -C, -DRB1 and -DQB1 allele and haplotype frequencies in the Serbian population. , 2014, Human immunology.

[38]  M. Mori,et al.  Neuromyelitis optica: Concept, immunology and treatment , 2014, Journal of Clinical Neuroscience.

[39]  Y. Itoyama,et al.  The Pathology of an Autoimmune Astrocytopathy: Lessons Learned from Neuromyelitis Optica , 2014, Brain pathology.

[40]  A. Wu,et al.  The complement and immunoglobulin levels in NMO patients , 2014, Neurological Sciences.

[41]  K. Fujihara,et al.  T cell-activation in neuromyelitis optica lesions plays a role in their formation , 2013, Acta neuropathologica communications.

[42]  S. Iida,et al.  Stevens–Johnson Syndrome associated with mogamulizumab treatment of adult T‐cell leukemia / lymphoma , 2013, Cancer science.

[43]  Edward Y. Chen,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[44]  S. Jarius,et al.  The expanding range of autoimmune disorders of the nervous system , 2013, The Lancet Neurology.

[45]  R. Herndon,et al.  Differentiation of neuromyelitis optica from multiple sclerosis on spinal magnetic resonance imaging. , 2012, International journal of MS care.

[46]  P. Evans,et al.  Bin2 Is a Membrane Sculpting N-BAR Protein That Influences Leucocyte Podosomes, Motility and Phagocytosis , 2012, PloS one.

[47]  J. Miller,et al.  Predicting the Functional Effect of Amino Acid Substitutions and Indels , 2012, PloS one.

[48]  J. Kira,et al.  Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[49]  Jacqueline A Palace,et al.  Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype , 2012, Neurology.

[50]  D. Wingerchuk,et al.  Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. , 2012, Archives of neurology.

[51]  M. Papadopoulos,et al.  Aquaporin 4 and neuromyelitis optica , 2012, The Lancet Neurology.

[52]  H. Kim,et al.  Clinical spectrum of CNS aquaporin-4 autoimmunity , 2012, Neurology.

[53]  A. Verkman,et al.  Complement-dependent Cytotoxicity in Neuromyelitis Optica Requires Aquaporin-4 Protein Assembly in Orthogonal Arrays* , 2012, The Journal of Biological Chemistry.

[54]  Jacqueline Palace,et al.  Serologic diagnosis of NMO , 2012, Neurology.

[55]  K. Kyvik,et al.  HLA, PTPN22 and PD-1 associations as markers of autoimmunity in neuromyelitis optica , 2012, Multiple sclerosis.

[56]  A. Lutterotti,et al.  Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders , 2011, Journal of Neuroinflammation.

[57]  R. Gibbs,et al.  Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 , 2011, Science.

[58]  A. McKenna,et al.  The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.

[59]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[60]  P. Visscher,et al.  GCTA: a tool for genome-wide complex trait analysis. , 2011, American journal of human genetics.

[61]  S. Olindo,et al.  Different HLA class II (DRB1 and DQB1) alleles determine either susceptibility or resistance to NMO and multiple sclerosis among the French Afro-Caribbean population , 2011, Multiple sclerosis.

[62]  P. Villoslada,et al.  [HLA-DRB1 typing in Caucasians patients with neuromyelitis optica]. , 2011, Revista de neurologia.

[63]  J. Parratt,et al.  Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes , 2010, Multiple sclerosis.

[64]  J. Honnorat,et al.  Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. , 2010, Brain : a journal of neurology.

[65]  X. Montalban,et al.  EFNS guidelines on diagnosis and management of neuromyelitis optica , 2010, European journal of neurology.

[66]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[67]  Brigitte Wildemann,et al.  AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance , 2010, Nature Reviews Neurology.

[68]  A. Lutterotti,et al.  Patterns of Antibody Binding to Aquaporin-4 Isoforms in Neuromyelitis Optica , 2010, PloS one.

[69]  Uthaman Gowthaman,et al.  Evaluation of different generic in silico methods for predicting HLA class I binding peptide vaccine candidates using a reverse approach , 2010, Amino Acids.

[70]  E. Donadi,et al.  HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis , 2010, Multiple sclerosis.

[71]  D. Wingerchuk Neuromyelitis optica: Effect of gender , 2009, Journal of the Neurological Sciences.

[72]  Y. Blanco,et al.  Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: An in vitro study , 2009, Journal of Neuroimmunology.

[73]  V. Lennon,et al.  Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. , 2009, Archives of neurology.

[74]  B. Ferry,et al.  A Novel Mutation in a Patient with a Deficiency of the Eighth Component of Complement Associated with Recurrent Meningococcal Meningitis , 2009, Journal of Clinical Immunology.

[75]  Rebecca A Robbins,et al.  Crystal structure of human aquaporin 4 at 1.8 Å and its mechanism of conductance , 2009, Proceedings of the National Academy of Sciences.

[76]  P. Vermersch,et al.  Is neuromyelitis optica associated with human leukocyte antigen? , 2009, Multiple sclerosis.

[77]  J. Kurtzke,et al.  An epidemiological study of neuromyelitis optica in Cuba , 2009, Journal of Neurology.

[78]  Vladimir Brusic,et al.  Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research , 2008, BMC Bioinformatics.

[79]  G. Remuzzi,et al.  Mutations in FN1 cause glomerulopathy with fibronectin deposits , 2008, Proceedings of the National Academy of Sciences.

[80]  F. Paul,et al.  Revised diagnostic criteria for neuromyelitis optica—incorporation of NMO-IgG status , 2007, Nature Clinical Practice Neurology.

[81]  J. Parisi,et al.  Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. , 2007, Brain : a journal of neurology.

[82]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[83]  Bernard de Bono,et al.  IRIS: a database surveying known human immune system genes. , 2005, Genomics.

[84]  Ichiro Nakashima,et al.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.

[85]  J. Kutok,et al.  Notch Oncoproteins Depend on γ-Secretase/Presenilin Activity for Processing and Function* , 2004, Journal of Biological Chemistry.

[86]  Massimo Filippi,et al.  Clinical characteristics, course and prognosis of relapsing Devic’s Neuromyelitis Optica , 2004, Journal of Neurology.

[87]  O. Lund,et al.  novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .

[88]  Y. Saeki,et al.  A Point Mutation of Tyr-759 in Interleukin 6 Family Cytokine Receptor Subunit gp130 Causes Autoimmune Arthritis , 2002, The Journal of experimental medicine.

[89]  Sergio Romagnani,et al.  Macrophage-Derived Chemokine and EBI1-Ligand Chemokine Attract Human Thymocytes in Different Stage of Development and Are Produced by Distinct Subsets of Medullary Epithelial Cells: Possible Implications for Negative Selection1 , 2000, The Journal of Immunology.

[90]  S. Wiese,et al.  Developmental Requirement of gp130 Signaling in Neuronal Survival and Astrocyte Differentiation , 1999, The Journal of Neuroscience.

[91]  Don C. Wiley,et al.  Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide , 1994, Nature.

[92]  P. Schneider,et al.  Genetic basis of human complement C8 beta deficiency. , 1993, Journal of immunology.

[93]  W. Sly,et al.  Mutational analysis of a patient with mucopolysaccharidosis type VII, and identification of pseudogenes. , 1993, American journal of human genetics.

[94]  W. Sly,et al.  Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. , 1973, The Journal of pediatrics.